NYSEAMERICAN : NSRX
Nasus Pharma Ltd. — Financial statements
Healthcare · Drug Manufacturers - General · Israel
Last price 3.07 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 35.96M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Financial statements
Income statement
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Selling, General & Admin | 5.60M | 2.67M | 743.00K | 580.00K | 926.00K |
| Research & Development | 4.53M | 2.23M | 335.00K | 567.00K | 1.12M |
| Operating Expenses | 10.13M | 4.90M | 1.08M | 1.15M | 2.04M |
| Operating Income | -10.13M | -4.90M | -1.08M | -1.15M | -2.04M |
| Interest Expense | -29.00K | -49.00K | -18.00K | ||
| Interest & Investment Income | 206.00K | 78.00K | |||
| Other Non Operating Income (Expenses) | -11.00K | -27.00K | -2.00K | -28.00K | -4.00K |
| EBT Excluding Unusual Items | -9.93M | -4.85M | -1.11M | -1.22M | -2.06M |
| Gain (Loss) on Sale of Investments | -626.00K | -952.00K | -443.00K | 219.00K | -88.00K |
| Pretax Income | -10.56M | -5.80M | -1.55M | -1.00M | -2.15M |
| Earnings From Continuing Operations | -10.56M | -5.80M | -1.55M | -1.00M | -2.15M |
| Earnings From Discontinued Operations | 13.00K | -51.00K | 20.00K | -46.00K | 441.00K |
| Net Income | -10.55M | -5.86M | -1.53M | -1.05M | -1.71M |
| Net Income to Common | -10.55M | -5.86M | -1.53M | -1.05M | -1.71M |
| Shares Outstanding (Basic) | 9.86M | 8.01M | 7.03M | 6.89M | 6.89M |
| Shares Outstanding (Diluted) | 9.86M | 8.01M | 7.03M | 7.06M | 6.89M |
| EPS (Basic) | -1.07 | -0.73 | -0.22 | -0.15 | -0.25 |
| EPS (Diluted) | -1.07 | -0.73 | -0.22 | -0.20 | -0.25 |
| Free Cash Flow | -10.54M | -4.93M | -665.00K | -1.03M | -1.21M |
| Free Cash Flow Per Share | -1.07 | -0.62 | -0.10 | -0.15 | -0.18 |
| EBIT | -10.13M | -4.90M | -1.08M | -1.15M | -2.04M |
Balance sheet
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Cash & Equivalents | 7.82M | 1.24M | 284.00K | 193.00K | 154.00K |
| Short-Term Investments | 4.00M | 3.05M | |||
| Cash & Short-Term Investments | 11.82M | 4.29M | 284.00K | 193.00K | 154.00K |
| Prepaid Expenses | 407.00K | 329.00K | 117.00K | 234.00K | 246.00K |
| Restricted Cash | 86.00K | 54.00K | 27.00K | 17.00K | 17.00K |
| Other Current Assets | 186.00K | 29.00K | |||
| Total Current Assets | 12.31M | 4.86M | 457.00K | 444.00K | 417.00K |
| Property, Plant & Equipment | 138.00K | 149.00K | |||
| Long-Term Deferred Charges | 260.00K | ||||
| Total Assets | 12.45M | 5.00M | 717.00K | 444.00K | 417.00K |
| Accounts Payable | 347.00K | 829.00K | 651.00K | 655.00K | 771.00K |
| Accrued Expenses | 568.00K | 786.00K | 879.00K | 616.00K | 345.00K |
| Short-Term Debt | 1.80M | 2.46M | 1.57M | ||
| Current Portion of Leases | 54.00K | 45.00K | |||
| Other Current Liabilities | 435.00K | 503.00K | 597.00K | 513.00K | 514.00K |
| Total Current Liabilities | 1.40M | 2.16M | 3.93M | 4.24M | 3.20M |
| Long-Term Leases | 49.00K | 73.00K | |||
| Total Liabilities | 1.45M | 2.24M | 3.93M | 4.24M | 3.20M |
| Common Stock | 20.00K | 19.00K | 4.00K | ||
| Additional Paid-In Capital | 35.46M | 21.29M | 9.43M | 7.32M | 7.29M |
| Retained Earnings | -24.46M | -18.52M | -12.66M | -11.13M | -10.08M |
| Shareholders' Equity | 11.00M | 2.77M | -3.21M | -3.80M | -2.79M |
| Total Liabilities & Equity | 12.45M | 5.00M | 717.00K | 444.00K | 417.00K |
| Total Debt | 103.00K | 118.00K | 1.80M | 2.46M | 1.57M |
| Net Cash (Debt) | 11.71M | 4.17M | -1.52M | -2.26M | -1.42M |
| Net Cash Per Share | 1.19 | 0.52 | -0.22 | -0.32 | -0.21 |
| Filing Date Shares Outstanding | 11.71M | 11.71M | 7.36M | 6.89M | 6.89M |
| Total Common Shares Outstanding | 11.71M | 9.02M | 7.36M | 6.89M | 6.89M |
| Working Capital | 10.91M | 2.69M | -3.47M | -3.80M | -2.79M |
| Book Value Per Share | 0.94 | 0.31 | -0.44 | -0.55 | -0.40 |
| Tangible Book Value | 11.00M | 2.77M | -3.21M | -3.80M | -2.79M |
| Tangible Book Value Per Share | 0.94 | 0.31 | -0.44 | -0.55 | -0.40 |
Cash flow statement
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Net Income | -10.55M | -5.86M | -1.53M | -1.05M | -1.71M |
| Loss (Gain) From Sale of Investments | 626.00K | 952.00K | 443.00K | -219.00K | 88.00K |
| Stock-Based Compensation | 810.00K | 447.00K | 10.00K | 39.00K | 23.00K |
| Other Operating Activities | -62.00K | 10.00K | 13.00K | 82.00K | -413.00K |
| Change in Accounts Payable | -344.00K | 152.00K | -5.00K | -116.00K | 150.00K |
| Change in Other Net Operating Assets | -908.00K | -567.00K | 410.00K | 283.00K | 327.00K |
| Operating Cash Flow | -10.52M | -4.92M | -665.00K | -1.03M | -1.21M |
| Capital Expenditures | -18.00K | -14.00K | |||
| Investment in Securities | -3.95M | -3.00M | |||
| Other Investing Activities | -160.00K | ||||
| Investing Cash Flow | -3.97M | -3.01M | -160.00K | ||
| Short-Term Debt Issued | 60.00K | 500.00K | |||
| Total Debt Issued | 60.00K | 500.00K | |||
| Net Debt Issued (Repaid) | 60.00K | 500.00K | |||
| Issuance of Common Stock | 22.14M | 8.92M | 1.00M | 995.00K | 969.00K |
| Other Financing Activities | 20.00K | -230.00K | -231.00K | ||
| Financing Cash Flow | 22.16M | 8.92M | 770.00K | 1.05M | 1.24M |
| Foreign Exchange Rate Adjustments | -8.00K | -4.00K | 13.00K | -10.00K | |
| Net Cash Flow | 7.67M | 980.00K | 101.00K | 39.00K | -143.00K |
| Free Cash Flow | -10.54M | -4.93M | -665.00K | -1.03M | -1.21M |
| Free Cash Flow Per Share | -1.07 | -0.62 | -0.10 | -0.15 | -0.18 |
| Levered Free Cash Flow | -6.98M | -3.04M | -260.88K | -542.50K | |
| Unlevered Free Cash Flow | -6.98M | -3.04M | -242.75K | -511.88K | |
| Change in Working Capital | -1.25M | -415.00K | 405.00K | 167.00K | 477.00K |
Ratios
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Market Capitalization | 37.60M | 82.90M | |||
| Enterprise Value | 25.89M | 85.26M | |||
| Last Close Price | 3.07 | 9.15 | |||
| PB Ratio | 3.27 | 29.95 | |||
| P/TBV Ratio | 3.50 | 29.95 | |||
| Debt / Equity Ratio | 0.01 | 0.04 | -0.56 | -0.65 | -0.56 |
| Net Debt / Equity Ratio | -1.06 | -1.51 | -0.47 | -0.60 | -0.51 |
| Net Debt / FCF Ratio | 1.11 | 0.84 | -2.28 | -2.20 | -1.17 |
| Quick Ratio | 8.42 | 1.98 | 0.07 | 0.05 | 0.05 |
| Current Ratio | 8.77 | 2.25 | 0.12 | 0.10 | 0.13 |
| Return on Assets (ROA) | -96.73% | -107.15% | -116.06% | -166.52% | |
| Return on Capital Employed (ROCE) | -91.70% | -172.60% | 33.60% | 30.20% | 73.30% |
| Earnings Yield | -33.33% | -7.06% | |||
| FCF Yield | -27.35% | -5.95% | |||
| Buyback Yield / Dilution | -38.03% | -13.98% | 0.43% | -2.44% |